Ligand id: 8299

Name: abaloparatide

No information available.
Summary of Clinical Use
The FDA granted abaloparatide approval in April 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Results from Phase 3 trial NCT01343004 evaluating abaloparatide has shown a reduced risk of new bone fractures in postmenopausal women receiving abaloparatide injection compared to placebo, with slight benefit over the already approved PTH analogue drug teriparatide [2]. There was also reduced incidence of hypercalcemia among women taking abaloparatide compared to those allocated to the teriparatide arm of the trial.
Mechanism Of Action and Pharmacodynamic Effects
Abaloparatide activates the parathyroid hormone receptors to stimulate osteoblast-dependent bone formation. It increases bone formation and bone mineral density.